The Japan presidents of foreign pharma companies are no longer hiding their concerns about the stagnation of drug development in the Japanese market. In their business briefings for 2021, many of them made explicit criticism against what they see as…
To read the full story
Related Article
- US FDA OKs Mitsubishi Tanabe’s Oral Edaravone for ALS
May 16, 2022
- Mitsubishi Tanabe’s Oral Edaravone Accepted for Swiss Review in ALS
April 26, 2022
- Mitsubishi Tanabe Eyes US Submission of Oral Edaravone by March-End
December 13, 2021
BUSINESS
- Sandoz Japan on Hunt for Biosimilar In-Licensing, Sales Tie-Ups after Avastin Deal
May 26, 2022
- Japan Pharma Market Up 3.3% in FY2021, Opdivo Rises to No.1: IQVIA
May 26, 2022
- Vabysmo, Ondexxya, Ozempic 2 mg Pen Now Available in Japan
May 26, 2022
- Novavax Vaccine Officially Added to Japan’s Free COVID-19 Inoculation Program
May 26, 2022
- BMS CEO Sees Faster Drug Development as Industry Imperative after COVID Vaccine Feat
May 25, 2022
The missing ingredient for managers is not their skill, ability, or education. Academic achievements and business success will get runs on the board, to a certain level. However, that is just half of the story.Leaders come in all shapes and…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…